Macquarie see further growth ahead for the CSL share price.As my Foolish colleague James reported yesterday, Macquarie has retained its outperform rating on the stock. It has a share price target of $329.50 on CSL shares. That’s a potential 16% upside.
The broker highlighted CSL’s successful recent phase 3 trial of garadacimab, which brings the hereditary angioedema treatment closer to approval.
According to CSL, the company “aims to begin filing with global health authorities at the end of the current fiscal year for full approval”.
If regulators give the go-ahead, Macquarie reckons it could command almost half of the market in the coming years.
In a company poll, Macquarie asked its experts to pick the best ASX 100 defensive shares to buy today.
CSL was among them due to its multiple growth drivers, as my colleague Brendan reported yesterday.
copy and paste
The Interest Rate Vomit Trade Has Happened, page-102
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$306.60 |
Change
4.560(1.51%) |
Mkt cap ! $148.1B | |||
| Open | High | Low | Value | Volume |
| $303.41 | $306.68 | $303.01 | $215.1M | 707.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3499 | $306.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $306.68 | 284 | 2 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |